Tasmania pilot to commence 1st March
February 22, 2024
Tasmanian pharmacists may be aware of the Tasmanian Community Pharmacy Program, scheduled to go live on 1 March 2024. Endorsed pharmacists practising in approved premises
Tasmanian pharmacists may be aware of the Tasmanian Community Pharmacy Program, scheduled to go live on 1 March 2024. Endorsed pharmacists practising in approved premises
Pharmacists have admirably navigated the changes to the provision of the Opioid Therapy Program (OTP) in 2023, overcoming numerous challenges whilst maintaining uninterrupted service to
The introduction of electronic prescriptions has improved patient accessibility to medication and reduced the administrative burden on pharmacies related to faxed or emailed prescriptions. Most
Psychostimulant changes The PDL Professional Officers would like to bring to the attention of NSW pharmacists some recent regulatory changes regarding the requirements to prescribe
The prescribing and supply of medicinal cannabis is a rapidly expanding area of practice in Australia. With this emerging field comes the need for comprehensive
Off-label prescribing occurs when a medication is used for a purpose that is not approved by the Australian Therapeutic Goods Administration (TGA). It may involve
In recent weeks, the PDL Professional Officers have received a number of queries regarding pharmacists’ obligations and liability when dispensing Mounjaro® (tirzepatide). Tirzepatide is a
Pharmacists have limited time left to register their interest in their pharmacy taking part in the NSW Pharmacy Trial, with the expression of interest process
The PDL Professional Officers often manage calls, incident reports and occasional regulatory complaints following a pharmacist’s decision to decline supply of a medication. Recently, the
Victorian pharmacists may be aware of the Community Pharmacist Statewide Pilot scheduled to go live towards the end of October. PDL continues to support the